Zobrazeno 1 - 10
of 1 169
pro vyhledávání: ''
Autor:
Eunice Y. Lau, Man Tong, Katherine Po Sin Chung, Terence K. Lee, Stephanie Ma, Rainbow Wing Hei Leung, Etienne H. Mok, Irene Oi-Lin Ng, Martina Mang Leng Lei, Q Zhao, Vincent W. Keng, Carmen Oi Ning Leung, Hoi Wing Leung, Cong Ma
Publikováno v:
Cancer Research. 81:3229-3240
The survival benefit derived from sorafenib treatment for patients with hepatocellular carcinoma (HCC) is modest due to acquired resistance. Targeting cancer stem cells (CSC) is a possible way to reverse drug resistance, however, inhibitors that spec
Autor:
Hsin-Fang Tu, Ming-Shyue Lee, Geen-Dong Chang, Santiago Ramón-Maiques, Chia-Chi Ku, Der-Yen Lee, Chao-Chi Ho, Hsin-Ying Lin, Ching-Tai Lee, Francisco Del Caño-Ochoa, Chun-Jung Ko, Ya-Hui Chuang, I-Chun Chen, Shao-Wei Lan, Hsin-Hsien Lin, Cheng-Fan Lee
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
13 páginas, 7 figuras
Current clinical trials of combined EGFR-tyrosine kinase inhibitors (TKI) and immune checkpoint blockade (ICB) therapies show no additional effect. This raises questions regarding whether EGFR-TKIs attenuate ICB-enhanced C
Current clinical trials of combined EGFR-tyrosine kinase inhibitors (TKI) and immune checkpoint blockade (ICB) therapies show no additional effect. This raises questions regarding whether EGFR-TKIs attenuate ICB-enhanced C
Autor:
Ki Hyun Yoo, Mi Hyeon Jang, Chang Hoon Cho, Alfredo Oliveros, Joseph A. Baur, Jason J. Tang, Mun Gyeong Bae, S. John Weroha, Jong Hoon Choi, Danielle Brogren, Xiaonan Hou, Mohammad Abdur Rashid, John R. Hawse, Ana Mia Corujo-Ramirez, Lindsey A Kirkeby
Publikováno v:
Cancer Res
Chemotherapy-induced cognitive impairment (CICI) is often reported as a neurotoxic side effect of chemotherapy. Although CICI has emerged as a significant medical problem, meaningful treatments are not currently available due to a lack of mechanistic
Autor:
David W. Cescon, Cunjie Zhang, Linda Z. Penn, Rosemary Yu, Emily Branchard, James W. Dennis, Richard R. Drake, Mohamad Elbaz, Joseph Longo, Jenna E. van Leeuwen
Publikováno v:
Cancer Research. 81:2625-2635
Aberrant N-glycan Golgi remodeling and metabolism are associated with epithelial–mesenchymal transition (EMT) and metastasis in patients with breast cancer. Despite this association, the N-glycosylation pathway has not been successfully targeted in
Autor:
Lin Zhang, Yali Liu, Shanu Modi, Sara A. Hurvitz, Yeon Hee Park, Javad Shahidi, Cristina Saura, Junji Tsurutani, Seock-Ah Im, Hiroji Iwata, Yoshinori Ito, Ian E. Krop, Keun Seok Lee, Neelima Denduluri, Kenji Tamura, Toshinari Yamashita, Joohyuk Sohn, Eriko Tokunaga, Caleb Lee, José Baselga, Christophe Perrin, Sung Bae Kim, Kenjiro Aogi, Fabrice Andre, Javier Cortes, Antoine Yver
Publikováno v:
Cancer Research. 81:PD3-06
Background Trastuzumab deruxtecan (T-DXd, DS-8201) is an antibody-drug conjugate with a HER2 antibody, tetrapeptide-based cleavable linker, and a novel topoisomerase I inhibitor payload. DESTINY-Breast01 (NCT03248492) is an open-label, international,
Autor:
Martin Olivo, Priyanka Sharma, Sara A. Hurvitz, Javier Cortes, Quan Hong, Eva Maria Ciruelos Gil, Sara M. Tolaney, Erika Hamiltion, Kevin Kalinsky, Joyce O'Shaughnessy, Philippe Aftimos, Loretta M. Itri, Linda T. Vahdat, Delphine Loirat, Lisa A. Carey, Véronique Diéras, Michaela Tsai, Tiffany A. Traina, Amelia Zelnak, David M. Goldenberg, Florence Dalenc, Sabela Recalde, Hope S. Rugo, Kevin Punie, Sagar Sardesai, Mafalda Oliveira, Aditya Bardia
Publikováno v:
Cancer Research. 81:GS3-06
Background: Trophoblast cell-surface antigen-2 (Trop-2) is highly expressed in many epithelial tumors, including triple-negative breast cancer (TNBC). Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2 antibody couple
Autor:
RL Moroose, Cheryl Aylesworth, K. Tkaczuk, Christine E. Simmons, Melody A. Cobleigh, Michaela Tsai, Erika Hamilton, Eva Harder Brix, Hugues Bourgeois, David Cameron, Hatem Soliman, Wentao Feng, Jorge Ramos, Michelina Cairo, Sherene Loi, Martin Andersson, Anthony Gonçalves, Mafalda Oliveira, Lisa A. Carey, Belinda Yeo, Paula R. Pohlmann, Alicia Okines, Mattea Reinisch
Publikováno v:
Cancer Research. 81:PD3-08
Background Tucatinib (TUC) is a highly selective oral tyrosine kinase inhibitor of HER2 with minimal inhibition of EGFR. It was recently approved by the FDA for patients (pts) with HER2+ metastatic breast cancer (MBC), including pts with brain metast
Autor:
Quan Hong, Martine Piccart, Delphine Loirat, Martin Olivo, Luca Gianni, Véronique Diéras, Sara A. Hurvitz, Aditya Bardia, Lisa A. Carey, Sibylle Loibl, Sara M. Tolaney, Joyce O'Shaughnessy, Loretta M. Itri, Hope S. Rugo, Javier Cortes, David M. Goldenberg, Kevin Punie, Kevin Kalinsky
Publikováno v:
Cancer Research. 81:PS11-09
Background: Trophoblast cell-surface antigen-2 (Trop-2) is highly expressed in many epithelial tumors, including triple-negative breast cancer (TNBC). Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2 antibody couple
Autor:
Ursa Brown-Glaberman, Jose I. Mayordomo, William J. Gradishar, Jennifer R. Diamond, Andrew Brenner, Pavani Chalasani, Alison Stopeck, Virginia F. Borges, Peter Kabos, Elena Shagisultanova
Publikováno v:
Cancer Research. 81:PS10-03
Background: In hormone receptor-positive / HER2-positive (HR+/HER2+) breast cancer, the HER2 and estrogen receptor (ER) signals merge on the cyclin D1-CDK4/6-RB1 pathway. Thus, a combined pharmacological intervention with individual drugs targeting H
Autor:
Alexander Melamed, Melissa Beauchemin, Melissa K. Accordino, Jason D. Wright, Dawn L. Hershman, Jacob C Cogan, Rohit R. Raghunathan
Publikováno v:
Cancer Research. 81:GS3-08
Introduction Cancer surgery has been linked to chronic opioid use post-operatively, with up to 10% of patients continuing to fill opioid prescriptions beyond 3 months after surgery. However, previous studies have not compared post-operative opioid us